Y-Intercept (HK)’s Harvard Bioscience HBIO Stock Holding History

Y-Intercept (HK)’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,694	Closed	-$7.52K	–	1755
2025 Q2	$7.52K	Buy	+1,694	New	+$7.08K	﹤0.01%	1584
2022 Q3	–	Sell	-1,464	Closed	-$53K	–	1094
2022 Q2	$53K	Buy	+1,464	New	+$66.1K	0.01%	746

Other funds holding HBIO

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Y-Intercept (HK)'s HBIO Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Harvard Bioscience (HBIO) in Q3 2025, closing a stake of 1,694 shares — an estimated $7.52K sold.

Y-Intercept (HK) first reported a position in HBIO in Q2 2022 and held it in 2 quarters. The position peaked at $53K in Q2 2022. 59 funds tracked by Wall St. Rank hold HBIO as of Q3 2025.

Y-Intercept (HK) reported no remaining Harvard Bioscience position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 1,694 Harvard Bioscience shares in Q3 2025, an estimated $7.52K.
Y-Intercept (HK) first reported a position in Harvard Bioscience in Q2 2022 and held it in 2 quarters.
Y-Intercept (HK)'s Harvard Bioscience position peaked at $53K in Q2 2022.
59 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.